Biomarker Analyses
tumor
TUMOR
In all four cohorts, increases in pharmacodynamic markers of focus from baseline to C1D8 suggested vascular remodeling activity and enhancement of antitumor immunity via IFNγ signaling (Analyses of changes in key biomarkers from baseline to C1D8 in all dosing cohorts (Among patients who had available tumor samples at screening and at C2D1, 10 patients had an immune-desert or immune-excluded phenotype at screening (As a result of the DLT, safety (including relative dose intensity), pharmacokinetic, efficacy, and biomarker analyses, the RP2D was determined to be E7389-LF 2.1 mg/m